BRCA1突变携带者预防性双侧输卵管卵巢切除术时行子宫切除术对浆液性/浆液样子宫癌的死亡降低与成本效益
基于近期前瞻性队列研究提示BRCA1突变携带者浆液性/浆液样子宫癌发病率升高,构建改良Markov决策模型,从支付方角度评估40岁时在降低风险双侧输卵管卵巢切除术(RRSO)同时行子宫切除术的生存获益与成本效益。结果显示联合子宫切除术较单纯RRSO额外获得4.9个月总生存,且成本更低,延迟子宫切除术在RRSO后25年内仍具成本效益。
要点
- 40岁BRCA1突变携带者RRSO联合子宫切除术较单纯RRSO额外获得4.9个月总生存。
- 单纯RRSO组终生发生和死于浆液性/浆液样子宫癌的概率分别为3.5%和2%。
- RRSO联合子宫切除术平均成本8803美元,低于单纯RRSO的9013美元。
核心结论
- 40岁BRCA1突变携带者在RRSO时加行子宫切除术平均额外获得4.9个月生命,且具有成本效益。
研究设计与样本
- 基于近期前瞻性队列研究的改良Markov决策模型,从支付方角度评估40岁时RRSO联合子宫切除术的决策。
主要发现
- 40岁行RRSO联合子宫切除术者较单纯RRSO额外获得4.9个月总生存(未贴现生命年40.38 vs 39.97)。
- 单纯RRSO组终生发生浆液性/浆液样子宫癌的概率为3.5%,死于该病的概率为2%。
- 单纯RRSO策略平均成本为9013美元,RRSO联合子宫切除术为8803美元,前者被后者支配(效果更差且成本更高)。
- 替代分析中,延迟子宫切除术仍为具成本效益的预防策略,40岁RRSO后随访至25年时ICER低于100000美元/年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To estimate the survival benefit and cost-effectiveness of performing hysterectomy during risk-reducing salpingo-oophorectomy (RRSO) for BRCA1 mutation carriers. METHODS: Based on a recent prospective cohort study indicating an elevated incidence of serous/serous-like uterine cancers among BRCA1 mutation carriers, we constructed a modified Markov decision model from a payer perspective to inform decisions about performance of hysterectomy during RRSO at age 40. We assumed patients had previously undergone a risk-reducing mastectomy and had a residual risk of death from breast or ovarian cancer. Disease-specific survival, age-adjusted competing hysterectomy rates, and deaths from other causes were incorporated. Costs of risk-reducing surgery, competing hysterectomy, and care for serous/serous-like uterine cancer were included. RESULTS: A 40year old woman who undergoes RRSO+Hysterectomy gains 4.9 additional months of overall survival (40.38 versus 39.97 undiscounted years) compared to RRSO alone. The lifetime probabilities of developing or dying from serous/serous-like uterine cancer in the RRSO group are 3.5% and 2%, respectively. The RRSO alone strategy has an average cost of $9013 compared to $8803 for RRSO+Hysterectomy, and is dominated (less effective and more costly) when compared to RRSO+Hysterectomy. In an alternative analysis, delayed hysterectomy remains a cost-effective prevention strategy with an ICER of less than $100,000/year for up to 25years following RRSO at age 40. CONCLUSIONS: The addition of hysterectomy to RRSO in a 40year old BRCA1 mutation carrier results in a mean gain of 4.9 additional months of life and is cost-effective.
引用
- Havrilesky LJ, Moss HA, Chino J, et al. Mortality reduction and cost-effectiveness of performing hysterectomy at the time of risk-reducing salpingo-oophorectomy for prophylaxis against serous/serous-like uterine cancers in BRCA1 mutation carriers. Gynecol Oncol. 2017. PMID: 28390820. doi:10.1016/j.ygyno.2017.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。